Qube Research & Technologies LTD Surface Oncology, Inc. Transaction History

Qube Research & Technologies LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.1 $2,973 - $5,947	-2,832 Reduced 8.54%	30,311 $32,000
Q2 2022 Aug 15, 2022	BUY	$1.42 - $3.15 $47,063 - $104,400	33,143 New	33,143 $54,000
Q1 2022 May 09, 2022	SELL	$2.65 - $5.08 $67,233 - $128,884	-25,371 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$4.73 - $7.9 $120,004 - $200,430	25,371 New	25,371 $121,000
Q3 2021 Nov 12, 2021	SELL	$5.16 - $7.98 $56,058 - $86,694	-10,864 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$6.45 - $9.09 $230,593 - $324,976	-35,751 Reduced 76.69%	10,864 $81,000
Q1 2021 May 14, 2021	SELL	$7.25 - $13.82 $540,335 - $1.03 Million	-74,529 Reduced 61.52%	46,615 $364,000
Q4 2020 Feb 16, 2021	BUY	$6.87 - $10.48 $197,938 - $301,949	28,812 Added 31.2%	121,144 $1.12 Million
Q3 2020 Nov 12, 2020	BUY	$5.06 - $7.23 $390,176 - $557,505	77,110 Added 506.57%	92,332 $637,000
Q2 2020 Aug 14, 2020	BUY	$1.57 - $6.56 $23,898 - $99,856	15,222 New	15,222 $100,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.